4h agoThe Motley FoolBEARISH 34General
Why Quest Diagnostics Holdings Stock Dropped Today
The government thinks it's been overpaying Quest Diagnostics. They plan to stop doing that next year.
Why Is QUEST DIAGNOSTICS IN (DGX) Stock Moving Today?
By the Top Tier Newswire AI Desk · September 22, 2026 at 11:08 AM ET · reviewed against 8 wire stories
QUEST DIAGNOSTICS IN (DGX) is drawing unusual attention today. Our newswire has captured 8 stories on DGX across 8 sources in the last 36 hours, with AI sentiment reading mixed (avg 51/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Quest Diagnostics (DGX) fell 5.29% to $231.92 in early trading on Tuesday, driven by a sharp premarket decline and weak intraday performance. The stock opened with a 6.5% gap down from the prior close of $244.88, reaching a session low of $227.00 shortly after the market opened. The move follows recent insider sales and broader market concerns, despite a recent price target increase from Truist.
What Happened
DGX opened at $229.01, significantly below the previous day's close, and traded down as much as 6.5% in the premarket session. The stock continued to struggle throughout the morning, with a low of $227.00 at 9:00 AM ET. Truist raised its price target for DGX to $260 from $250, but the move did not provide immediate support. Meanwhile, recent insider transactions at Quest Diagnostics show three sales totaling $8.3 million in the last 90 days, including sales by the CEO and other executives. These exits may have added to investor caution.
The stock's decline also occurred amid broader market volatility. The 10-year Treasury yield rose above 5%, and oil prices surged past $105 per barrel, contributing to a risk-off sentiment. Additionally, CMS announced new Medicare lab payment rates that could lead to $1 billion in annual savings by 2027, raising questions about the company's long-term profitability in a highly regulated sector.
What The Data Shows
DGX traded at 0.7 times its 3-month average volume, indicating moderate liquidity but not unusual activity. The stock is currently within its 52-week range of $171.18 to $248.84 and has a beta of 0.55, suggesting it is less volatile than the broader market. The company reported trailing 12-month revenue growth of 9.9%, but its net margin of 9.2% and P/E ratio of 26.0 suggest investors are paying a premium for its earnings. Recent insider sales and the broader market's risk-off tone appear to be the key factors influencing the stock's performance.
What To Watch
The stock is expected to remain under pressure in the near term as investors assess the impact of the CMS payment changes and the broader macroeconomic environment. Truist's revised price target may provide a potential floor, but earnings or further guidance from Quest Diagnostics could offer more clarity in the coming weeks.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
DGX by the numbers
Coverage: 8 stories / 8 sourcesAI sentiment: 51/100 (mixed)Mkt cap: $27.2BP/E: 26.052w: $171.18 to $248.84
The headlines behind the move
7h agoBarchartNEUTRAL 53General
Is Quest Diagnostics Stock Outperforming the Nasdaq?
8h agoCNBCNEUTRAL 50General
Stocks making the biggest moves premarket: Alibaba, Quest Diagnostics, On Holding, GameStop & more
These are the stocks posting the largest moves in early trading.
8h agoSeeking AlphaBEARISH 38General
At a glance: stocks gapping down premarket
Stock futures dip Tuesday as Nasdaq rally fades; see premarket gap-down movers Endava (DAVA) and Quest Diagnostics (DGX) and what’s driving the slide—read...
22h agoInvesting.com MarketsNEUTRAL 48General
Why is Quest Diagnostics stock sliding today?
Why is Quest Diagnostics stock sliding today?
1d agoYahoo FinanceBULLISH 67Product/PR
Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges
Quest Diagnostics (NYSE:DGX) CEO and President Jim Davis said the diagnostic testing company is exceeding the growth framework it outlined at its prior investor day, driven largely by organic growth, consumer-health demand and partnerships rather than a heavier-than-expected pace of acquisitions. D
1d agoPR NewswireBULLISH 55General
Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics
Study published in JAMA Network Open of over 193,000 patients nationwide reveals that individuals with evidence of exposure to Borrelia burgdorferi, the bacterium that causes Lyme disease, are more than four times as likely to have antibodies against other tick-borne pathogens compared to...
1d agoThe FlyBULLISH 61Analyst
Quest Diagnostics price target raised to $260 from $250 at Truist
Frequently asked questions
Why is DGX stock moving today?
QUEST DIAGNOSTICS IN (DGX) is drawing unusual attention today. Our newswire has captured 8 stories on DGX across 8 sources in the last 36 hours, with AI sentiment reading mixed (avg 51/100). The most recent driver: "Why Quest Diagnostics Holdings Stock Dropped Today" (The Motley Fool).
Is DGX a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of DGX coverage reads 51/100 over 8 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is VKTX up today (+35.54%)
- Why is MAZE up today (+27.19%)
- Why is XNDU down today (-21.78%)
- Why is BFLY up today (+21.31%)
- Why is VICR up today (+18.76%)
- Why is INOD up today (+15.86%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on DGX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier DGX move explainers: 2026-09-22